- Home
- NEN vs CLLS Comparison
NEN vs CLLS Comparison
Compare NEN & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NEN
- CLLS
- Stock Information
- Founded
- NEN 1977
- CLLS 1999
- Country
- NEN United States
- CLLS France
- Employees
- NEN N/A
- CLLS N/A
- Industry
- NEN Building operators
- CLLS Biotechnology: Pharmaceutical Preparations
- Sector
- NEN Real Estate
- CLLS Health Care
- Exchange
- NEN Nasdaq
- CLLS Nasdaq
- Market Cap
- NEN 262.4M
- CLLS 143.4M
- IPO Year
- NEN N/A
- CLLS 2007
- Fundamental
- Price
- NEN $73.02
- CLLS $1.59
- Analyst Decision
- NEN
- CLLS Buy
- Analyst Count
- NEN 0
- CLLS 1
- Target Price
- NEN N/A
- CLLS $4.00
- AVG Volume (30 Days)
- NEN 594.0
- CLLS 48.2K
- Earning Date
- NEN 01-01-0001
- CLLS 08-05-2025
- Dividend Yield
- NEN 6.49%
- CLLS N/A
- EPS Growth
- NEN 58.97
- CLLS N/A
- EPS
- NEN 4.56
- CLLS N/A
- Revenue
- NEN $82,531,485.00
- CLLS $54,747,000.00
- Revenue This Year
- NEN N/A
- CLLS $48.52
- Revenue Next Year
- NEN N/A
- CLLS $5.17
- P/E Ratio
- NEN $16.22
- CLLS N/A
- Revenue Growth
- NEN 6.12
- CLLS 351.26
- 52 Week Low
- NEN $68.98
- CLLS $1.10
- 52 Week High
- NEN $84.00
- CLLS $2.43
- Technical
- Relative Strength Index (RSI)
- NEN 47.71
- CLLS 56.98
- Support Level
- NEN $73.00
- CLLS $1.56
- Resistance Level
- NEN $73.25
- CLLS $1.49
- Average True Range (ATR)
- NEN 0.22
- CLLS 0.09
- MACD
- NEN 0.16
- CLLS 0.01
- Stochastic Oscillator
- NEN 67.11
- CLLS 80.00
About NEN New England Realty Associates Limited Partnership Depositary Receipts Evidencing Units of Limited Partnership
New England Realty Associates LP is engaged in the business of acquiring, developing, holding for investment, operating and selling real estate. The Partnership owns and operates various residential apartments, condominium units and commercial properties located in Massachusetts and New Hampshire. The company generates revenue from rental income from residential and commercial properties recognized over the term of the related lease. The long-term goals of the Partnership are to manage, rent and improve its properties and to acquire additional properties with income and capital appreciation potential as suitable opportunities arise.
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.